Biological response modifiers for the treatment of Crohn’s disease

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.4, Iss.11, 2004-11, pp. : 1719-1727

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Infliximab use in Crohn’s disease

By Bewtra Meenakshi Lichtenstein Gary R

Expert Opinion on Biological Therapy, Vol. 5, Iss. 4, 2005-04 ,pp. : 589-599

Informa Healthcare

Access to resources Recommend Favorite

Antitumour necrosis factor therapy in Crohn’s disease

By Kaser Arthur Tilg Herbert

Expert Opinion on Biological Therapy, Vol. 2, Iss. 7, 2002-10 ,pp. : 715-721

Informa Healthcare

Access to resources Recommend Favorite

A comparative analysis of the molecular genetic processes in the pathogenesis of psoriasis and Crohn’s disease

By Piruzian E. Ishkin A. Nikol’skaya T. Abdeev R. Bruskin S.

Molecular Biology, Vol. 43, Iss. 1, 2009-02 ,pp. : 159-165

MAIK Nauka/Interperiodica

Access to resources Recommend Favorite

The role of biological response modifiers in malignant melanoma

By Lens Marko B

Expert Opinion on Biological Therapy, Vol. 3, Iss. 8, 2003-12 ,pp. : 1225-1231

Informa Healthcare

Access to resources Recommend Favorite

Certolizumab pegol in the treatment of Crohn's disease

By Ferrante Marc Vermeire Séverine Rutgeerts Paul

Expert Opinion on Biological Therapy, Vol. 13, Iss. 4, 2013-04 ,pp. : 595-605

Informa Healthcare

Access to resources Recommend Favorite